IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Myeloproliferative neoplasms (MPNs) are characterized by the clonal expansion of one or more myeloid cell lineage. In most cases, proliferation of the malignant clone is ascribed to defined genetic alterations. MPNs are also associated with aberrant expression and activity of multiple cytokines; however, the mechanisms by which these cytokines contribute to disease pathogenesis are poorly understood. Here, we reveal a non-redundant role for steady-state IL-33 in supporting dysregulated myelopoiesis in a murine model of MPN. Genetic ablation of the IL-33 signaling pathway was sufficient and necessary to restore normal hematopoiesis and abrogate MPN-like disease in animals lacking the inositol phosphatase SHIP. Stromal cell-derived IL-33 stimulated the secretion of cytokines and growth factors by myeloid and non-hematopoietic cells of the BM, resulting in myeloproliferation in SHIP-deficient animals. Additionally, in the transgenic JAK2V617F model, the onset of MPN was delayed in animals lacking IL-33 in radio-resistant cells. In human BM, we detected increased numbers of IL-33-expressing cells, specifically in biopsies from MPN patients. Exogenous IL-33 promoted cytokine production and colony formation by primary CD34+ MPN stem/progenitor cells from patients. Moreover, IL-33 improved the survival of JAK2V617F-positive cell lines. Together, these data indicate a central role for IL-33 signaling in the pathogenesis of MPNs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765 · cited 1×
“The long-term outcome of CML patients has substantially improved with the use of the tyrosine kinase inhibitor imatinib, yet its efficacy may be hampered by the action of cytokines (6).”
Helgason, C. D., Damen, J. E., Rosten, P., Grewal, R., Sorensen, P., Chappel, S. M., Borowski, A., Jirik, F., Krystal, G., & Humphries, R. K. (1998) · Genes & Development · doi:10.1101/gad.12.11.1610 · Cited by 556
Liu, Q., Sasaki, T., Kozieradzki, I., Wakeham, A., Itie, A., Dumont, D. J., & Penninger, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.7.786 · Cited by 341
Long-term IL-33–producing epithelial progenitor cells in chronic obstructive lung disease
Byers, D. E., Alexander-Brett, J., Patel, A. C., Agapov, E., Dang-Vu, G., Jin, X., Wu, K., You, Y., Alevy, Y., Girard, J.-P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65570 · Cited by 337
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335 · cited 1×
“For instance, blockade of IL-6 signaling only partially corrects the aberrant hematopoiesis in SHIP-deficient (28) or transgenic BCR-ABL1 mice (4).”
Risks of myeloid malignancies in patients with autoimmune conditions
Anderson, L. A., Pfeiffer, R. M., Landgren, O., Gadalla, S., Berndt, S. I., & Engels, E. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604935 · Cited by 253
CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation
Allakhverdi, Z., Comeau, M. R., Smith, D. E., Toy, D., Endam, L. M., Desrosiers, M., Liu, Y.-J., Howie, K. J., Denburg, J. A., Gauvreau, G. M., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.10.022 · Cited by 234
Influence of SHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation
Wang, J.-W., Howson, J. M., Ghansah, T., Desponts, C., Ninos, J. M., May, S. L., Nguyen, K. H. T., Toyama-Sorimachi, N., & Kerr, W. G. (2002) · Science · doi:10.1126/science.1068438 · Cited by 178
Cited by
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
Self-citationInterleukin-33 in health and disease
Liew, F. Y., Girard, J.-P., & Turnquist, H. R. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.95 · Cited by 1,147
Interleukin‐33 (IL‐33): A nuclear cytokine from the IL‐1 family
Cayrol, C., & Girard, J. (2018) · Immunological Reviews · doi:10.1111/imr.12619 · Cited by 879
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Kralovics, R. (2017) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 616
Cytokine-Induced Modulation of Colorectal Cancer
Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00096 · Cited by 216
“This indicates that the nuclear function of IL-33 as a regulator of gene transcription (197) and its role as a soluble cytokine upon secretion (198) may promote CRC pathogenesis in this model.”
BackgroundSelf-citation
Metadata
- Authors
- Mager, L. F., Riether, C., Schürch, C. M., Banz, Y., Wasmer, M.-H., Stuber, R., Theocharides, A. P., Li, X., Xia, Y., Saito, H., Nakae, S., Baerlocher, G. M., Manz, M. G., McCoy, K. D., Macpherson, A. J., Ochsenbein, A. F., Beutler, B., & Krebs, P.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-05-26
- Volume
- 125
- Issue
- 7
- Pages
- 2579-2591
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1751099384
- Cited by
- 92
- References
- 8
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1172/jci77347
- The paper
- Mager, L. F., Riether, C., Schürch, C. M., Banz, Y., Wasmer, M.-H., Stuber, R., Theocharides, A. P., Li, X., Xia, Y., Saito, H., Nakae, S., Baerlocher, G. M., Manz, M. G., McCoy, K. D., Macpherson, A. J., Ochsenbein, A. F., Beutler, B., & Krebs, P. (2015). IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. Journal of Clinical Investigation. https://doi.org/10.1172/jci77347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.